Clinical trial IJB-SYNERGY-012017
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer. Synergy Trial (IJB-SYNERGY-012017)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Institut Jules Bordet |
| EudraCT Identifier | 2017-004651-23 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03616886 |
| Inclusion criteria | Metastatic. ER-/PR-/HER2- |
| Last update |